Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Common Equity: 2020-2025

Historic Common Equity for Caribou Biosciences (CRBU) over the last 6 years, with Sep 2025 value amounting to $141.8 million.

  • Caribou Biosciences' Common Equity fell 49.56% to $141.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.8 million, marking a year-over-year decrease of 49.56%. This contributed to the annual value of $253.0 million for FY2024, which is 31.34% down from last year.
  • As of Q3 2025, Caribou Biosciences' Common Equity stood at $141.8 million, which was down 14.62% from $166.1 million recorded in Q2 2025.
  • Caribou Biosciences' Common Equity's 5-year high stood at $404.4 million during Q3 2021, with a 5-year trough of -$47.7 million in Q2 2021.
  • Its 3-year average for Common Equity is $275.2 million, with a median of $278.3 million in 2023.
  • Data for Caribou Biosciences' Common Equity shows a peak YoY increase of 3,707.18% (in 2021) and a maximum YoY decrease of 1,201.26% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Caribou Biosciences' Common Equity stood at $387.8 million in 2021, then declined by 22.42% to $300.9 million in 2022, then increased by 22.44% to $368.4 million in 2023, then slumped by 31.34% to $253.0 million in 2024, then slumped by 49.56% to $141.8 million in 2025.
  • Its last three reported values are $141.8 million in Q3 2025, $166.1 million for Q2 2025, and $217.2 million during Q1 2025.